The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF).

C. N. Harrison

Consultant or Advisory Role - Celgene; Incyte; Novartis; S*Bio; Shire

J. Kiladjian

Consultant or Advisory Role - Novartis

H. K. Al-Ali

Consultant or Advisory Role - Amgen; Celgene; Novartis

Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Novartis

Research Funding - Celgene; Novartis

H. Gisslinger

Consultant or Advisory Role - Novartis

Honoraria - Novartis

R. J. Waltzman

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

V. Stalbovskaya

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

M. McQuitty

Employment or Leadership Position - Novartis

Stock Ownership - Novartis

D. S. Hunter

Employment or Leadership Position - Incyte

Stock Ownership - Incyte

R. S. Levy

Employment or Leadership Position - Incyte

Stock Ownership - Incyte

F. Cervantes

Consultant or Advisory Role - Bristol-Myers Squibb; Novartis

A. M. Vannucchi

Consultant or Advisory Role - Novartis

T. Barbui

Consultant or Advisory Role - Italfarmaco; Novartis

G. Barosi

Expert Testimony - Novartis (U)